Skip to content
10-Q

Quarterly Report

ARTELO BIOSCIENCES, INC. ARTL

0001640334-26-000869

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 2.33M sh
Shares Diluted Q1 2026 · Mar 31, 2026 739K sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 189K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.19M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.6M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $10.27M
Stockholders Equity Q1 2026 · Mar 31, 2026 $6.67M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$1.27M
Stockholders Equity Q1 2026 · Mar 31, 2025 $652K
Stockholders Equity Q1 2026 · Dec 31, 2024 $2.86M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.83M
Current Liabilities Q1 2026 · Dec 31, 2025 $4.04M
Total Liabilities Q1 2026 · Mar 31, 2026 $5.85M
Total Liabilities Q1 2026 · Dec 31, 2025 $4.07M
Current Assets Q1 2026 · Mar 31, 2026 $10.42M
Current Assets Q1 2026 · Dec 31, 2025 $695K
Total Assets Q1 2026 · Mar 31, 2026 $12.52M
Total Assets Q1 2026 · Dec 31, 2025 $2.8M
Eps Diluted Q1 2026 · Mar 31, 2026 −$4.00
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$12.55
Sga Expense Q1 2026 · Mar 31, 2026 $1.92M
Sga Expense Q1 2026 · Mar 31, 2025 $995K
Rd Expense Q1 2026 · Mar 31, 2026 $773K
Rd Expense Q1 2026 · Mar 31, 2025 $1.38M
Net Income Q1 2026 · Mar 31, 2026 −$2.96M
Net Income Q1 2026 · Mar 31, 2025 −$2.37M
Operating Income Q1 2026 · Mar 31, 2026 −$2.69M
Operating Income Q1 2026 · Mar 31, 2025 −$2.38M